| Literature DB >> 36012479 |
Delphine Martineau-Côté1,2, Allaoua Achouri1, Janitha Wanasundara3, Salwa Karboune2, Lamia L'Hocine1.
Abstract
Faba beans are a promising emerging plant-based protein source to be used as a quality alternative to peas and soy. In this study, the potential health beneficial activities of three Canadian faba bean varieties (Fabelle, Malik and Snowbird) were investigated after in vitro gastrointestinal digestion and compared to two commonly used legumes (peas and soy). The results revealed that the faba beans had a higher antioxidant activity than peas when assessed with the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) assays, except for the Fabelle variety. In the oxygen radical absorbance capacity (ORAC) and the iron chelating assays, the faba beans had a lower antioxidant activity than soy. Interestingly, Fabelle and Snowbird showed a higher antioxidant effect than the peas and soy at the cellular level. The antihypertensive properties of Fabelle and Malik varieties were significantly higher than peas but lower than soy. The in vitro antidiabetic activity was higher for soy, but no differences were found at the cellular level. The faba bean peptides were further fractionated and sequenced by mass spectrometry. Eleven peptides with in silico predicted bioactivities were successfully identified in the faba bean digestate and support validating the health-promoting properties of peptides. The results demonstrate the bioactive potential of faba beans as a health-promoting food ingredient against non-communicable diseases.Entities:
Keywords: Angiotensin-Converting Enzyme inhibitors; Dipeptidyl Peptidase-IV inhibitors; antidiabetic; antihypertensive; antioxidant; bioactive peptides; faba bean; gastrointestinal digestate; pulse protein
Mesh:
Substances:
Year: 2022 PMID: 36012479 PMCID: PMC9409335 DOI: 10.3390/ijms23169210
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Statistical significance of the studied digestion conditions and faba bean peptide concentration on cell viability as assessed by two-way ANOVA.
| Factor | |
|---|---|
|
| |
| Bile salt concentration | 0.285 |
| Peptide concentration |
|
| Bile salt concentration × Peptide concentration | 0.774 |
|
| |
| Intestinal enzyme used |
|
| Peptide concentration |
|
| Intestinal enzyme used × Peptide concentration |
|
|
| |
| Protease inhibitor concentration |
|
| Peptide concentration |
|
| Protease inhibitor concentration × Peptide concentration |
|
1 Values significant at the 5% level are printed in bold-faced type.
Figure 1The impact of various concentrations (3000, 3500 and 4000 μg peptides/mL) of 3 kDa permeate of faba bean digestate (variety Fabelle) obtained in different digestion conditions on Caco-2 cell viability. The digestions were performed with different (a) bile salts concentrations; (b) different intestinal enzyme combinations; (c) different protease inhibitor (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF)) concentrations. Data are expressed as mean ± standard deviation of three experiments and means without a common letter differ (p < 0.05) as analyzed by two-way ANOVA and the Tukey’s test.
Figure 2Impact of different concentrations (3000, 3500 and 4000 μg peptides/mL) of 3 kDa permeate of legume digestates obtained in the optimized digestion conditions (AEBSF 1 mM, bile salt 10 mM, pancreatin and peptidase) on cell viability. Data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by two-way ANOVA and the Tukey’s test.
Figure 3In silico prediction of bioactive fragments released during gastrointestinal digestion of (a) faba bean; (b) pea; (c) and soy main storage proteins.
Figure 4(a) Molecular weight distribution of peptides; and (b) exhibited antihypertensive activity of the faba bean digestate (variety Fabelle) before and after 3 kDa cut-off ultrafiltration. The ACE inhibition data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Figure 5Molecular weight distribution of peptides in the 3 kDa permeate of legume digestates as assessed by size exclusion HPLC.
Composition analysis of the 3 kDa permeate of legume digestates.
| % Proteins | Total Polyphenol | Total Carbohydrates | |
|---|---|---|---|
| (Dry Base) | |||
| Fabelle | 34.37 ± 0.22 b | 4.81 ± 0.19 a | 43.5 ± 1.6 b |
| Malik | 36.11 ± 0.47 c | 4.97 ± 0.25 a | 44.0 ± 2.0 b |
| Snowbird | 38.42 ± 0.27 d | 4.80 ± 0.31 a | 45.2 ± 0.5 b |
| Amarillo | 32.87 ± 0.17 a | 4.43 ± 0.17 a | 46.7 ± 1.5 b |
| AAC-26-15 | 54.49 ± 0.54 e | 4.81 ± 0.51 a | 16.6 ± 0.8 a |
Data are expressed as mean ± standard deviation and means in a column without a common letter differ (p <0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Figure 6Antioxidant activity of the 3 kDa permeate of legume digestates as assessed by (a) the 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assay; (b) the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay; (c) the oxygen radical absorbance capacity (ORAC); (d) the iron chelating assay; and (e) the cellular antioxidant assay (CAA). Data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Figure 7Antihypertensive activity (Angiotensin-Converting Enzyme inhibition) of the 3 kDa permeate of legume digestates. Data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Figure 8Antidiabetic activity (Dipeptidyl-Peptidase-IV inhibition) of the 3 kDa permeate of legume digestates: (a) in vitro assay with a purified Dipeptidyl-Peptidase-IV from porcine kidney; (b) inhibition assay in a cellular model. Data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Figure 9Peptide fractionation of the 3 kDa permeate of Fabelle in vitro gastrointestinal digestate by size exclusion HPLC. F1, fraction 1; F2, fraction 2; F3, fraction 3.
Figure 10Angiotensin-Converting Enzyme inhibition of faba bean (variety Fabelle) peptide-enriched fractions (F1, F2 and F3). Data are expressed as mean ± standard deviation and means without a common letter differ (p < 0.05) as analyzed by one-way ANOVA and the Tukey’s test.
Antioxidant activity of faba bean (variety Fabelle) peptide-enriched fractions (F1, F2 and F3).
| ABTS 1 | Iron Chelating 2 | ORAC | |
|---|---|---|---|
| F1 | 41.5 ± 10.4 c | 67.6 ± 2.7 b | 0.7 ± 0.5 b |
| F2 | 98.9 ± 0.8 a | 54.1 ± 1.8 c | 3.2 ± 0.6 a |
| F3 | 71.4 ± 15.3 b | 88.5 ± 1.9 a | 3.1 ± 0.1 a |
1 Fractions were tested at 40 µg/mL; 2 Fractions were tested at 5 µg/mL; Data are expressed as mean ± standard deviation and means with different letter in a column are statistically different (p <0.05) as analyzed by one-way ANOVA and the Tukey’s test.
LC-MS/MS identified faba bean peptides and their respective precursor proteins found in the peptide-enriched fractions of the 3 kDa permeate of Fabelle in vitro gastrointestinal digestate.
| Peptide Sequence | Fraction | Observed Mass (Da) | Calculated Mass (Da) | ppm 1 | Precursor Protein | Protein Accession Number | Fragment Location |
|---|---|---|---|---|---|---|---|
| N2YDEGSEPR | F1 | 1066.421 | 1066.420 | 0.43 | Convicilin | B0BCL8 | 29–37 |
| PVNRPGEPQ | F1 | 992.507 | 992.504 | 2.60 | Vicilin | I0B569 | 152–160 |
| LDNIN2ALEPDH | F1 | 1250.578 | 1250.578 | −0.19 | Legumin B | P05190.1 | 35–45 |
| TETWNPNHPE | F1 | 1223.522 | 1223.521 | 1.21 | Legumin B | P05190.1 | 52–61 |
| TETWNPNHPEL | F1 | 1336.606 | 1336.605 | 0.88 | Legumin B | P05190.1 | 52–62 |
| EEEDEDEPR | F1 | 1146.436 | 1146.431 | 3.64 | Legumin | Q43673 | 327–335 |
| KEEEDEDEPR | F1 | 1274.530 | 1274.526 | 3.06 | Legumin | Q43673 | 326–335 |
| VIPTEPPH | F1 | 888.470 | 888.471 | −0.70 | Tonoplast intrinsic protein 32 | A0A024NRI7 | 155–162 |
| VIPTEPPHA | F1 | 959.508 | 959.508 | −0.13 | Tonoplast intrinsic protein 32 | A0A024NRI7 | 155–163 |
| VVIPTEPPHA | F1 | 1058.577 | 1058.576 | 0.55 | Tonoplast intrinsic protein 32 | A0A024NRI7 | 154–163 |
| VVIPTEPPH | F1 and F2 | 987.540 | 987.539 | 1.07 | Tonoplast intrinsic protein 32 | A0A024NRI7 | 154–162 |
Amino acids are abbreviated with 1 letter code; 1 Mass error was expressed in ppm and calculated as follow: ; 2 Deamidation of asparagine residue.
In silico prediction of bioactive properties of the LC-MS/MS identified faba bean peptides using the BIOPEP-UWM database.
| Peptide Sequence | Fraction | Potential Bioactivity 1 | Bioactive Fragments | A 2 | B 3 (μM−1) |
|---|---|---|---|---|---|
| NYDEGSEPR | F1 | ACE inhibitor | PR, GS, EG, NY | 0.44 | 0.03 |
| Stimulating 5 | SE | 0.11 | . | ||
| DPP-IV inhibitor | EP, EG, NY, YD | 0.44 | . | ||
| DPP-III inhibitor | PR | 0.11 | . | ||
| PVNRPGEPQ | F1 | Anti-amnestic | PG | 0.11 | . |
| ACE inhibitor | GEP, RP, GE, PG, PQ | 0.56 | 0.36 | ||
| Antithrombotic | PG | 0.11 | . | ||
| Regulating 4 | PG | 0.11 | . | ||
| DPP-IV inhibitor | RP, EP, GE, NR, PG, PQ, PV, VN | 0.89 | 4.96 | ||
| DPP-III inhibitor | GE | 0.11 | . | ||
| Renin inhibitor | NR | 0.11 | . | ||
| LDNINALEPDH | F1 | ACE inhibitor | ALEP | 0.09 | 1.44 × 10−5 |
| DPP-IV inhibitor | EP, AL, DN, IN, NA | 0.45 | 1.03 × 10−4 | ||
| TETWNPNHPE | F1 | ACE inhibitor | TE, HP | 0.2 | . |
| Antioxidant | TW | 0.1 | . | ||
| Alpha-glucosidase inhibitor | PE | 0.1 | 3.99 × 10−6 | ||
| DPP-IV inhibitor | HP, NP, WN, ET, NH, PN, TE, TW | 0.8 | 3.35 × 10−3 | ||
| DPP-III inhibitor | HP, PE | 0.2 | . | ||
| TETWNPNHPEL | F1 | ACE inhibitor | TE, HP | 0.18 | . |
| Antioxidant | EL, PEL, TW, TETWNPNHPEL | 0.36 | . | ||
| Alpha-glucosidase inhibitor | PE | 0.09 | 3.63 × 10−6 | ||
| DPP-IV inhibitor | HP, NP, WN, ET, NH, PN, TE, TW | 0.73 | 3.04 × 10−3 | ||
| DPP-III inhibitor | HP,PE | 0.18 | . | ||
| EEEDEDEPR | F1 | ACE inhibitor | PR | 0.11 | 0.03 |
| Stimulating 5 | EEE, EE | 0.33 | . | ||
| DPP-IV inhibitor | EP | 0.11 | . | ||
| DPP-III inhibitor | PR | 0.11 | . | ||
| KEEEDEDEPR | F1 | ACE inhibitor | PR, KE | 0.2 | 0.02 |
| Stimulating 5 | EEE, EE | 0.3 | . | ||
| DPP-IV inhibitor | EP, KE | 0.2 | . | ||
| DPP-III inhibitor | PR | 0.1 | . | ||
| VIPTEPPH | F1 | ACE inhibitor | IP, TE, PT, PP, PH | 0.63 | 9.62 × 10−4 |
| Alpha-glucosidase inhibitor | PP | 0.13 | 6.93 × 10−6 | ||
| DPP-IV inhibitor | PP, IP, EP, PH, PT, TE, VI | 0.88 | 3.26 × 10−4 | ||
| VIPTEPPHA | F1 | ACE inhibitor | IP, TE, PT, PP, PH | 0.56 | 8.55 × 10−4 |
| Antioxidant | PHA | 0.11 | . | ||
| Alpha-glucosidase inhibitor | PP | 0.11 | 6.16 × 10−6 | ||
| DPP-IV inhibitor | PP, HA, IP, EP, PH, PT, TE, VI | 0.89 | 2.90 × 10−4 | ||
| VVIPTEPPHA | F1 | ACE inhibitor | IP, TE, PT, PP, PH | 0.5 | 7.69 × 10−4 |
| Antioxidant | PHA | 0.1 | . | ||
| Alpha-glucosidase inhibitor | PP | 0.1 | 5.55 × 10−6 | ||
| DPP-IV inhibitor | PP, VV, HA, IP, EP, PH, PT, TE, VI | 0.9 | 2.61 × 10−4 | ||
| VVIPTEPPH | F1 and F2 | ACE inhibitor | IP, TE, PT, PP, PH | 0.56 | 8.55 × 10−4 |
| Alpha-glucosidase inhibitor | PP | 0.11 | 6.16 × 10−6 | ||
| DPP-IV inhibitor | PP, VV, IP, EP, PH, PT, TE, VI | 0.89 | 2.90 × 10−4 |
Amino acids are abbreviated with 1 letter code; 1 Potential bioactivities for each peptide were determined using the BIOPEP-UWM database [69]; 2 The parameter A represents the occurrence frequency of a fragment with a given bioactivity: , where a is the number of fragments with a given bioactivity and N is the number of amino acid residues in the peptide sequence [70]; 3 The parameter B represents the potential biological activity of the peptide: , where a is the number of repetitions of a given fragment with a given activity, EC50 is its respective half maximum activity (μM) and k is the number of different fragments with a given bioactivity and N is the number of amino acid residues [70]. The B parameter is only calculated if EC50 data are available. The higher the B value is, the higher the predicted bioactivity is. A and B were automatically computed by the BIOPEP algorithm; 4 Peptide regulating the stomach mucosal membrane activity; 5 Peptide stimulating vasoactive substance release.
UniProtKB Protein accession numbers of faba bean, pea and soy main storage proteins used for the in silico analysis.
| Faba Bean ( | |||
| Proteins | Gene | Accession Number | |
| Legumin (11S) | Legumin B | LEB4 | P05190 |
| LEB2 | P16078 | ||
| LEB6 | P16079 | ||
| LEB7 | P16080 | ||
| Legumin A | A1 | Q03971 | |
| A2 | Q99304 | ||
| Vicilin (7S) | Vicilin | . | P08438 |
| Convicilin | . | B0BCL8 | |
| . | B0BCL7 | ||
| Pea ( | |||
| Proteins | Gene | Accession Number | |
| Legumin (11S) | Legumin B | LEGJ | P05692 |
| LEGK | P05693 | ||
| LEGB | P14594 | ||
| Legumin A | A | P02857 | |
| A2 | P15838 | ||
| Vicilin (7S) | Vicilin | . | P13918 |
| Convicilin | CVA | P13915 | |
| CVB | P13919 | ||
| Soy ( | |||
| Proteins | Gene | Accession Number | |
| Glycinin (11S) | Glycinin-G1 | GY1 | P04776 |
| Glycinin-G2 | GY2 | P04405 | |
| Glycinin-G3 | GY3 | P11828 | |
| Glycinin-G4 | GY4 | P02858 | |
| Glycinin-G5 | GY5 | P04347 | |
| β-Conglycinin (7S) | β-Conglycinin-α’ | CG-1 | P11827 |
| β-Conglycinin-α | CG-3 | P0DO16 | |
| β-Conglycinin β | CG-4 | P25974 | |